916325-84-3

Basic information

• Product Name: ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat
• Synonyms: Ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylate;Methyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylate;3-a]pyriMidine-7-carboxylat;ethyl 5-chloro-[1;Methyl 5-broMo-1H-pyrazol...;5-bromo-1H-Pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester;ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat
• CAS NO: 916325-84-3
• Molecular Formula: C₈H₆BrN₃O₂
• Molecular Weight: 256.06
• Product Categories: CHIRAL CHEMICALS
• Mol File: 916325-84-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 394.9±37.0 °C(Predicted)
• Appearance: /
• Density: 1.798 g/cm³
• Refractive Index: 1.689
• Storage Temp.: 2-8°C
• PKA: 6.59±0.40(Predicted)
• CAS DataBase Reference: ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat(916325-84-3)
• EPA Substance Registry System: ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat(916325-84-3)

Safety Data

• Hazardous Substances Data: 916325-84-3(Hazardous Substances Data)

Usage

Description

Ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat is a chemical compound that belongs to the class of triazolopyrimidines. It is characterized by the presence of a chloro substituent at the 5-position and an ethyl ester group at the 7-position. ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat has potential applications in various fields due to its unique chemical structure and properties.

Uses

Used in Pharmaceutical Industry:
Ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat is used as an intermediate in the synthesis of indazole-containing macrocycles. These macrocycles are being developed for the treatment of disorders characterized by the activation of the Wnt pathway signaling. The Wnt pathway plays a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. Dysregulation of this pathway has been implicated in several diseases, such as cancer and neurodegenerative disorders.
In the synthesis of indazole-containing macrocycles, ethyl 5-chloro-[1,2,4]triazolo[4,3-a]pyrimidine-7-carboxylat serves as a key building block, providing the necessary structural features for the formation of the macrocyclic framework. The resulting macrocycles can then be further optimized and evaluated for their potential therapeutic effects in modulating the Wnt pathway and treating related disorders.

InChI:InChI=1/C8H7ClN4O2/c1-2-15-7(14)5-3-6(9)13-4-10-12-8(13)11-5/h3-4H,2H2,1H3

Upstream product

• 916325-83-2 pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 55676-21-6 3-acetyl-2-chloropyridine 
• 109-09-1 2-chloropyridine 
• 116834-96-9 3-methyl-1H-pyrazolo[3,4b]pyridine 
• 131674-39-0 2-chloro-3-(1-hydroxyethyl)pyridine 
• 116855-08-4 1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 885223-65-4 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine 
• 67-56-1 methanol 
• 916325-85-4 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 117007-52-0 3-iodo-1H-pyrazolo[3,4-b]pyridine 

Downstream Products

• 916325-85-4 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid 
• 916326-80-2 5-bromo-1methyl-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid methyl ester 
• 1314734-59-2 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazolo[3,4-b]pyridine-3-carbaldehyde 
• 916327-20-3 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid {2-amino-4-[2-(tert-butyl-dimethyl-silanyloxy)-ethoxy]-phenyl}-amide 
• 916326-42-6 5-bromo-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acid [2-amino-3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-amide 

Relevant articles and documents

INDAZOLE CONTAINING MACROCYCLES AND THERAPEUTIC USES THEREOF

Indazole macrocycle compounds of formula (I) for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. Formula (I)

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

Provided herein are compounds according to Formulas (I) or (II) and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, osteoarthritis, idiopathic pulmonary fibrosis and neurological conditions/disorders/diseases.